Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Nabavi

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Immunity|May 1, 1994
In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2C Chen, N Nabavi
Infection and Immunity|February 1, 1986
Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformansN Nabavi, J W Murphy
Infection and Immunity|October 1, 1985
In vitro binding of natural killer cells to Cryptococcus neoformans targetsN Nabavi, J W Murphy
Lupus|June 26, 2014
Correlation between serum 25(OH)D values and lupus disease activity: an original article and a systematic review with meta-analysis focusing on serum VitD confoundersM Sahebari, N Nabavi, M Salehi
Surgical Neurology|December 1, 1978
Deep seated giant arteriovenous malformations in infancyE C Ventureyra, L P Ivan, N Nabavi
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1994
Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 moleculeC Chen, A Gault, L Shen, et al.
Infection and Immunity|April 1, 1991
Binding interactions of murine natural killer cells with the fungal target Cryptococcus neoformansJ W Murphy, M R Hidore, N Nabavi
Infection and Immunity|May 1, 1991
Murine natural killer cells are fungicidal to Cryptococcus neoformansM R Hidore, N Nabavi, F Sonleitner, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1993
Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunityS Baskar, N Nabavi, L H Glimcher, et al.
The Journal of Infectious Diseases|December 1, 1996
Blockade of CD86 ameliorates Leishmania major infection by down-regulating the Th2 responseJ A Brown, R G Titus, N Nabavi, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Immunity|May 1, 1994
In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2C Chen, N Nabavi
Infection and Immunity|February 1, 1986
Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformansN Nabavi, J W Murphy
Infection and Immunity|October 1, 1985
In vitro binding of natural killer cells to Cryptococcus neoformans targetsN Nabavi, J W Murphy
Lupus|June 26, 2014
Correlation between serum 25(OH)D values and lupus disease activity: an original article and a systematic review with meta-analysis focusing on serum VitD confoundersM Sahebari, N Nabavi, M Salehi
Surgical Neurology|December 1, 1978
Deep seated giant arteriovenous malformations in infancyE C Ventureyra, L P Ivan, N Nabavi
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1994
Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 moleculeC Chen, A Gault, L Shen, et al.
Infection and Immunity|April 1, 1991
Binding interactions of murine natural killer cells with the fungal target Cryptococcus neoformansJ W Murphy, M R Hidore, N Nabavi
Infection and Immunity|May 1, 1991
Murine natural killer cells are fungicidal to Cryptococcus neoformansM R Hidore, N Nabavi, F Sonleitner, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1993
Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunityS Baskar, N Nabavi, L H Glimcher, et al.
The Journal of Infectious Diseases|December 1, 1996
Blockade of CD86 ameliorates Leishmania major infection by down-regulating the Th2 responseJ A Brown, R G Titus, N Nabavi, et al.
Pageof 5